Skip to main content

Table 2 Virologic failures with RPV + bDRV

From: Effectiveness and safety of dual therapy with rilpivirine and boosted darunavir in treatment-experienced patients with advanced HIV infection: a preliminary 24 week analysis (RIDAR study)

Patient Baseline VL Previous ART VL at time of VF Observations
1 33 ABC/3TC + DRV/r 81–393 Resuppression without switch (continued on RPV + bDRV)
No drug resistance mutations.
2 159 ETV + DRV/r 67–96 Switch to cART (to include omeprazol).
No genotyping.
3 759 ETV + DRV/r 560–7530 Switch to RPV+ bDRV + DTG
No genotyping.
4 210 ETV + DRV/r 191–131 Resuppression without switch (continued on RPV + bDRV)
No genotyping.
5 < 50 ETV + DRV/r 16,500 (390 five days later) Poor adherence
No switch (continued on RPV + bDRV)
No genotyping.
6 < 50 ETV + RAL + DRV/r 270–1197 Switch to ETV + DRV/r (post-switch VL of 23 copies)
No drug resistance mutations
7 < 50 ETV + RAL + ATV/r 220–612 Switch to ABC/3TC + DRV/r
No drug resistance mutations
8 95 TDF/FTC + NVP 173,000-1590 Poor adherence
No genotyping
  1. VL: viral load; ART: antiretroviral therapy; VF: virological failure; ABC: abacavir; 3TC:
  2. lamivudine; DRV: darunavir; bDRV: boosted darunavir; ETV: etravirine; RAL: raltegravir; RPV: rilpivirine; TDF: tenofovir; ATV: atazanavir; NVP: nevirapine; DTG:
  3. dolutegravir